Can you have federal question jurisdiction in a case where no federal claim is alleged?  The question has a certain self-defining quality to it, sort of like asking if something done under the table can be above board.  Or asking whether the Holy Roman Empire was holy, Roman, or an empire.

We stole that last

We were wondering when the courts would catch on to this Catch 22.  In order to survive preemption, plaintiffs suing the manufacturers of pre-market approved (“PMA”) medical devices have to allege “parallel claims” in which all “common-law” claims must be genuinely equivalent to violations of FDA regulations. But under Grable & Sons Metal Products, Inc.

As we’ve mentioned before, we watch state-law litigation over genetically-modified organisms (“GMOs”) because they tend to produce interesting results on federalism issues such as preemption, since anti-GMO zealots often try to interpose state law to gum up the works of federal regulatory decisions that they don’t like.  Those results are applicable by analogy (at

In honor of Buddy Ryan, the legendary football coach who passed away last week, we will be especially crotchety in today’s case report.  It was while we were in law school in Chicago that Ryan was the coordinator of a Bears defense that was magnificently ferocious.  When the 1985 Bears won the Super Bowl, Ryan was carried off the field.  Never before or since has an assistant coach been so honored.  Ryan later went to Philadelphia, as did we.  (His arrival was slightly more ballyhooed.)  Ryan became the most beloved Eagles coach ever, though his teams never mustered a single playoff win.  Ryan is so revered here because he built a defense that fit the city’s self-image – blue collar and brutal.  It was fun watching Reggie White, Jerome Brown, Clyde Simmons, and Mike Golic maul quarterbacks.  It was fun watching Andre Waters and Wes Hopkins terrify opposing receivers.  It was fun watching linebacker Seth Joyner wreak havoc all over the field.  It was less fun watching an Eagles offense that defined the word erratic.  Aside from achievements on the field, Ryan cut the ultimate figure of pure orneriness.   He was a genuine hero in the Korean War (fighting alongside Dan Blocker, who later played Hoss in Bonanza).  Sports-and-war analogies are overused and overheated, but Ryan’s coaching style was undeniably bellicose.  He put a bounty on Dallas Cowboy players, rewarding his players for maiming America’s team.  Ryan once punched a fellow coach on the sidelines.  He had such contempt for a player that he offered to trade him for a six-pack, and the beer didn’t “even have to be cold.” Philly is a hard-core union town, and Ryan earned big-time props by refusing to coach scab players during a NFL labor dispute. Ryan guested on one of Philly’s notoriously hostile sports-talk shows and, after a caller criticized a trade, Ryan said something like, “Gee, I’m all broken-up about your opinion.”

We’re all broken up about the opinion in Oregon v. General Nutrition Corp., 2010 U.S. Dist. LEXIS 78038 (D. Oregon March 30, 2016).  It is not a drug or device case, but its treatment of removal and federal question is relevant for our work, and not in a good way.  The state of Oregon brought an action in Oregon state court (talk about home field advantage) alleging that the defendant had misrepresented that certain products were “lawful dietary supplements” when they actually contained substances forbidden (according to the state) by federal law.  While the claims were brought under Oregon law, those claims also referenced, indeed, completely turned on, an interpretation of the federal Food, Drug and Consumer Act.  The defendant removed the case to federal court.  Oregon moved to remand back to state court.  The issue was whether there was federal jurisdiction.  Both species of federal jurisdiction were in play here, federal question and diversity jurisdiction.   We will devote this piece to federal question jurisdiction, because the diversity issue is too squirrely. (In brief: a state as party cannot support diversity jurisdiction, so the defendant needed to show that the state was not the true plaintiff.  The court did not buy this argument.)

It sure seems like Oregon was raising a federal question.  Were the substances at issue permitted or forbidden by federal law?  You’ll never learn the answer to that question from this opinion.  Presumably (but, as you’ll see, we’re against presuming), that intricate issue of regulatory construction will be entrusted to good and true jurors. The court began its jurisdictional analysis with an extended riff on the “strong presumption” against finding removal jurisdiction.  We get loads about how the “burden of establishing federal subject-matter jurisdiction for purposes of removal is on the party seeking removal.”  We’ve heard all this before.  But why is there a presumption against removal jurisdiction?  It is hardly self-evident. Why is the burden on the poor defendant, who never asked to be sued?  Shouldn’t the burden be on the plaintiff, as most burdens are?  You can say that federal courts are courts of limited jurisdiction, but what court isn’t?  When we prosecuted misdemeanor cases in California state courts, we were required to prove that the crime was committed in the court’s county.  Not every case could be brought into that court.  So enough with the limited jurisdiction rationale. Isn’t the discussion of presumptions and burdens nothing more than a judicial fig leaf?  Whenever courts spill ink on presumptions and burdens, they inevitably follow-up with an analysis that claims the issue isn’t even close.  The presumption was not necessary at all, was it?

Continue Reading Why is Federal Question Jurisdiction Such a Mess?

Strict liability is not the same as absolute liability.  We learned that truth in law school, but too many plaintiff lawyers and judges seem to have unlearned it along the way.  The key separator between strict liability and absolute liability is comment k to section 402A of the Restatement (Second) of Torts (1965), which observes

Starting with our comprehensive post lambasting Schrecengost v. Coloplast Corp., 425 F. Supp.3d 448 (W.D. Pa. 2019), for ignoring 75 years of hitherto unbroken Pennsylvania precedent and allowing a “strict liability” design defect claim against an FDA-regulated prescription medical product, we have both chronicled and opposed the other side’s attempt to infiltrate strict liability into Pennsylvania litigation involving such products (primarily medical devices). That attempt disregards seven Pennsylvania Supreme Court decisions between 1948 (Henderson) and 2014 (Lance), as well as the Pennsylvania Superior Court (an intermediate appellate court in Pennsylvania) (Creazzo), all rejecting application of strict liability principles to prescription medical products.  For the gory details, see the prior post.

Continue Reading Pennsylvania Law, Federal Rules, and FDA Standards

This post is from the non-Reed Smith side of the blog.

We don’t usually report on securities-law cases, but today we do. That is because the well-reasoned decision in question, In re Allergan PLC Securities Litigation, 2022 WL 17584155 (S.D.N.Y. 2022), has major implications for the parallel Textured Breast Implant MDL now pending in

We wrote recently that California’s courts have never met a case they did not like.  We were speaking somewhat tongue in cheek of course, but still California remains a destination for litigation tourists trying to take advantage of laws and procedures that many view as plaintiff friendly.  One bulwark against blatant forum shopping is personal jurisdiction under the U.S. Supreme Court’s Bauman and Bristol-Myers Squibb cases, the latter reversing the California Supreme Court, which restored some measure of discipline to jurisdiction over out-of-state defendants.

Another potential bulwark is choice of law.  That is to say, even when a plaintiff sues in California, the applicable choice-of-law rules might compel the application of another state’s law, which could doom the plaintiff’s claims.

That is what happened this week in Nelson v. F. Hoffmann-La Roche, Inc., No. 21-cv-10074, 2022 WL 17259056 (N.D. Cal. Nov. 28, 2022) (to be published in F. Supp. 3d), where a Florida resident and Army veteran used a generic prescription drug while stationed in Kentucky and overseas and allegedly suffered complications.  But he chose to sue in California.  Why?  Because the manufacturer of the branded version of the drug (not the generic version that the plaintiff actually used) was based in California at the time he filed (having relocated from New Jersey), and California is one of a very few states that allows innovator liabilityi.e., holding an innovator/branded manufacturer potentially liable for a generic product that it did not make, did not sell, and from which it did not make any profit. 

Continue Reading Federal Judge In California Cabins Innovator Liability